31JUL

Alchemab wins Bank's record £25m cheque

2 min read

12:32UTC

Alchemab Therapeutics raised a £25m Series A extension on 9 July, the British Business Bank's largest-ever direct life-sciences cheque, for AI-enabled antibody discovery.

← Back to Humanoid hit $1.35bn on a customer order Jump to analysis ↓

TechnologyAssessed

Key takeaway

Alchemab's £25m is the Bank's biggest life-sciences bet, staking public money on AI antibody discovery.

Alchemab Therapeutics, a British antibody-discovery biotech, raised a £25m Series A extension on 9 July, the largest direct life-sciences investment the British Business Bank has ever made, to push an AI-enabled antibody-discovery pipeline toward the clinic ¹.

Alchemab hunts for protective antibodies in people who resist diseases they should have caught, then turns those molecules into drug candidates. The method leans on machine learning to sift immune repertoires at a scale no bench scientist could match, placing it in the same AI-meets-biology tier as IMU Biosciences, which raised £40m in June .

The cheque puts the state directly on a life-sciences cap table rather than behind a fund manager. For a Bank criticised for leading none of the year's marquee AI rounds, backing Alchemab plants a flag in a field where British Science still leads. Someone still has to run those assays, and the government published a plan to build that workforce the same afternoon.

Deep Analysis

In plain English

Alchemab Therapeutics is a Cambridge biotech using artificial intelligence to find antibodies, proteins the immune system makes to fight disease, that could become new drugs. On 9 July it raised £25m as an extension to an earlier funding round, and all of it came from the British Business Bank, a state-owned bank that invests in growing UK companies. It is the largest single life-sciences investment the Bank has ever made directly. The money should let Alchemab keep developing its antibody candidates towards human clinical trials without needing to raise again from private investors in the near term.

Deep Analysis

Root Causes

Alchemab's cheque exists because the Bank's mandate changed in April: for the first time it can lead venture rounds and invest directly up to £60m per company, rather than only co-investing alongside private leads as it did in IMU Biosciences' £40m round.

Pre-clinical antibody discovery is capital-intensive with a long return horizon, a profile private venture funds have grown warier of funding alone since 2023; the Bank's expanded mandate exists specifically to backstop that gap in patient capital.

What could happen next?

Meaning
The Bank's willingness to write £25m directly into a pre-clinical biotech signals it now treats life-sciences extension rounds as within its risk appetite, not just seed-stage deeptech.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The Bank contributed £12m to Cytospire Therapeutics' £61m Series A in May, one investor among a syndicate led by 4BIO Capital; Alchemab's £25m two months later, with the Bank as sole backer, shows the size of a single Bank life-sciences cheque roughly doubling in the space of two months.

Counter-parallel: In Oxford Quantum Circuits' £260m Series C, the Bank was one of nine co-investors in a syndicate led by Bullhound Capital; Alchemab is the opposite structure, a single-investor cheque with no syndicate at all, a role the Bank has not previously taken at this size in life sciences.

Immediate effect: £25m extends Alchemab's runway toward clinical-stage antibody candidates without the down round or bridge financing pre-clinical biotechs often need when a Series A closes before trial data reads out.

Structurally, this is the Bank's largest direct life-sciences cheque under the £6.6bn mandate it has held since April, a scale test of whether a state investor can underwrite biotech risk at a size previously reserved for specialist life-sciences funds.

Consensus view: The BioIndustry Association's general position is that the UK's life-sciences financing gap sits at Series A extension and Series B, not seed, where US and European AI-biotech comparators typically outspend British rounds by two to three times; the Bank's £25m cheque targets exactly that stage.

Counter-view: Some UK venture investors argue a government-backed direct-equity cheque can crowd out the private syndicates that would otherwise lead extension rounds, since Bank capital can anchor a round on terms private investors did not set, echoing the dynamic already visible in IMU Biosciences' £40m raise , where the Bank co-invested rather than led.

Key tension: Whether the Bank's willingness to write the largest cheque should be read as filling a genuine market gap or as substituting for private capital that has grown more risk-averse toward pre-clinical antibody discovery.

Sources:British Business Bank

Mentions:Bullhound Capital →Oxford Quantum Circuits →Trimtech Therapeutics →British Business Bank →IMU Biosciences →Cytospire Therapeutics →Cambridge →Alchemab Therapeutics →

First Reported In

Update #11 · Britain funds and defunds its own science

British Business Bank· 14 Jul 2026

Read original →

Causes and effects

Caused by

IMU raises £40m to read blood

IMU Biosciences' £40m June round set the AI-biotech benchmark that Alchemab's £25m cheque extends.

Occurred 2 Jun 2026

Read story →

Jobs plan targets the lab-skills gap

The Jobs Plan answers the staffing gap that Alchemab's £25m cheque assumes is already solved.

Occurred 9 Jul 2026

Read story →

This Event

Alchemab wins Bank's record £25m cheque

The investment puts UK public money directly on a biotech cap table, not behind a fund manager, in a sector British science still leads.

Different Perspectives

Fubon Financial

Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.

NATO Innovation Fund

The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.

Prime Movers Lab

Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.

Bosch and Schaeffler

Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.

UK founders raising seed through Series A

A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.

EQT

EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.